Pliant结束特发性肺纤维化资产bexotegrast的开发

2025-06-28 04:32

Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results.
In March, the company ended the BEACON-IPF trial following a Data Safety Monitoring Board recommendation. Analysis of data found that bexotegrast-treated participants had an increased risk of experiencing adverse events associated with IPF disease progression
In May, Pliant cut ~45% of its workforce.
The pharma said it will continue development of PLN-101095, an oral candidate in a phase 1 open-label trial as monotherapy and in combination with Keytruda (pembrolizumab) in solid tumors resistant to immune checkpoint inhibitors.
Pliant is up ~13% in after-hours trading Friday.

More on Pliant Therapeutics